Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

111.00p
   
  • Change Today:
    -2.00p
  • 52 Week High: 148.50
  • 52 Week Low: 101.00
  • Currency: UK Pounds
  • Shares Issued: 106.23m
  • Volume: 27,966
  • Market Cap: £117.92m
  • RiskGrade: 281

Cello to up the tempo

Date: Tuesday 13 Mar 2012

LONDON (ShareCast) - Market insight and strategic marketing combo Cello has whacked up its full year dividend by a fifth, despite one off costs turning earnings per share negative.

Headline profit before tax, which excludes amortisation, impairment and restructuring costs, rose 10.2% to £7.1m in 2011 from £6.4m in 2010, in line with market expectations.

Reported profit before tax, however, tumbled to £1.4m from £4.9m, to the indifference of the market, which chased the shares as high as 39p at one point, up 3.5p on the day, before the share price ebbed back to 37.5p.

Impairment of goodwill and intangibles took a £2.5m chunk out of profits, while restructuring costs also took a bite, rising to £0.95m from £0.82m the year before, after the company failed to retain a large retail contract in 2011.

The £2.5m impairment charge related largely to the decision to close its London-based mass media ("above the line" in ad-land jargon) agency, though more challenging recent trading conditions for its communications business, Tangible, were also a factor.

Amortisation of intangibles in 2011 rose to £1.20m from £0.34m the year before, while acquisition costs reduced profits by a further £0.21m (2010: nil).

Once the tax-man had taken his £1.63m rake (up from £1.31m the year before), the group found itself sitting on a loss of £0.27m, compared to a profit the previous year of £3.61m.

Basic headline earnings per share declined 15.1% to 6.71p in 2011 from 7.90p, while the reported loss per share was 0.81p, against positive diluted earnings per share of 5.23p the year before.

Despite making a loss, the management signalled confidence in the future with a full year dividend of 1.72p, up 20.3% from 1.43p the year before.

Away from all the accountancy jiggery-pokery, the net debt position also improved, narrowing to £7.7m at the end of 2011 from £8.8m the year before, helped by earn-out provisions - fees the company is obliged to pay the former owners of companies it has acquired - tumbling to £3.2m from £7.3m the year before.

Talking of acquisitions, the purchase of MedErgy, a healthcare communications specialist, has been deemed a success.

The acquisition strengthened the group's focus on healthcare, a sector the group likes because of its high margins and high barriers to entry.

MedErgy has contributed £5.1m to revenue and £1.3m to profit before tax for the period between the date of acquisition (March) and the end of 2011.

"2011 saw a continuation of the group's solid performance and delivery on our strategy of internationalising revenues and growing our pharmaceutical expertise. As a result we are seeing good momentum in the business, demonstrated by our strong cash flow and considerably strengthened balance sheet," Chief Executive Mark Scott said.

"We are confident that our focus on servicing international clients in the pharmaceutical and other high margin sectors with our innovative digital offerings will continue to drive growth," Scott added.

Allan Rich, non-executive Chairman of Cello, said the group began 2012 with a solid order book and has achieved a good level of forward bookings so far this year.

"At this early stage of the year, the board is optimistic that current expectations for 2012 can be met," Rich said.


jh

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 111.00p
Change Today -2.00p
% Change -1.77 %
52 Week High 148.50
52 Week Low 101.00
Volume 27,966
Shares Issued 106.23m
Market Cap £117.92m
RiskGrade 281

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
66.51% below the market average66.51% below the market average66.51% below the market average66.51% below the market average66.51% below the market average
67.57% above the sector average67.57% above the sector average67.57% above the sector average67.57% above the sector average67.57% above the sector average
Price Trend
46.34% above the market average46.34% above the market average46.34% above the market average46.34% above the market average46.34% above the market average
7.32% above the sector average7.32% above the sector average7.32% above the sector average7.32% above the sector average7.32% above the sector average
Income
9.26% below the market average9.26% below the market average9.26% below the market average9.26% below the market average9.26% below the market average
86.67% above the sector average86.67% above the sector average86.67% above the sector average86.67% above the sector average86.67% above the sector average
Growth
40.89% below the market average40.89% below the market average40.89% below the market average40.89% below the market average40.89% below the market average
44.44% below the sector average44.44% below the sector average44.44% below the sector average44.44% below the sector average44.44% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Final Interim
Ex-Div 23-Apr-20 03-Oct-19
Paid 22-May-20 01-Nov-19
Amount 2.95p 1.15p

Trades for 01-Apr-2020

Time Volume / Share Price
09:49 966 @ 108.46p
08:14 12,000 @ 108.30p
08:14 12,000 @ 108.00p
08:05 3,000 @ 108.36p

Cello Health Key Personnel

CEO Mark Scott

Top of Page